Trials / Completed
CompletedNCT01318733
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 449 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD07805/47 gel 0.5% | In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months. |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-06-01
- Completion
- 2012-07-01
- First posted
- 2011-03-18
- Last updated
- 2021-02-18
- Results posted
- 2014-01-08
Locations
27 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01318733. Inclusion in this directory is not an endorsement.